CN103417591A - Traditional Chinese medicine composition for treating cerebral apoplexy and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating cerebral apoplexy and preparation method thereof Download PDFInfo
- Publication number
- CN103417591A CN103417591A CN2012101637304A CN201210163730A CN103417591A CN 103417591 A CN103417591 A CN 103417591A CN 2012101637304 A CN2012101637304 A CN 2012101637304A CN 201210163730 A CN201210163730 A CN 201210163730A CN 103417591 A CN103417591 A CN 103417591A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- radix
- apoplexy
- acanthopanacis senticosi
- caulis acanthopanacis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for treating cerebral apoplexy and a preparation method thereof. The composition contains pseudo-ginseng, acanthopanax, Ligusticum wallichii, etc., and the prescription of the pharmaceutical composition is simple and effective.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of Chinese medicine composition for the treatment of apoplexy and preparation method thereof.
Background technology
Apoplexy (Stroke) is the formal name used at school of apoplexy, it is a kind of cerebral blood circulation obstacle disease of unexpected onset, be again cerebrovascular accident, the patient who refers at cerebrovascular disease, because various risk factors cause that internal artery is narrow, inaccessible or break, and cause the acute brain disturbance of blood circulation, show as clinically a sings and symptoms of crossing property or permanent disordered brain function.Apoplexy is the common refractory disease of serious harm human health and life security, and motherland's medical science is classified it as first of " wind, consumptive disease, distension, diaphragm " four large difficult disease, exists obvious three-hypers (sickness rate is high, disability rate is high, mortality rate high) phenomenon.Reach 2,000,000 according to the annual patient with cerebral apoplexy that occurs of statistics China.Sickness rate is up to 1,20/,100,000.The stroke patient 7,000,000 of now surviving, wherein 4,500,000 patients disability and can't take care of oneself in various degree.Disability rate is up to 75%.China's annual stroke patient dead 1,200,000.Must cross the patient of apoplexy, also easily recur again, every recurrence once, increases the weight of once.Apoplexy causes great threat to human health and life, to the patient, brings very big misery, and family and society bring heavy burden.
Hypertension, diabetes, heart disease, metabolism disorder of blood lipid, transient ischemic attack, smoking and excessive drinking, hemorheology are disorderly and fat etc. may be all the risk factor of apoplexy, the symptom at apoplexy initial stage be dizziness, numb limbs and tense tendons, temporary pronounce indistinctly or talk ineffective, limb adynamia or movable ineffective, fall suddenly or fall in a swoon etc. from different at ordinary times headache, unknown cause, have a strong impact on orthobiosis.Apoplexy is divided into ischemic (transient ischemic attack, Atherosclerosis and thrombosis and cerebral infarction, lacunar infarction, cerebral embolism) and the large class of hemorrhagic (cerebral hemorrhage, subarachnoid hemorrhage) two, cause that by angiemphraxis ischemia apoplexy claims again cerebral infarction, accounts for the 70%-80% of apoplexy.In cerebrovascular sudden death event, cerebral infarction accounts for 80%, and cerebral infarction occurs suddenly, can make the patient lethal, disable.Cerebral infarction refers to that the local feeding artery blood perfusion of the cerebral tissue of unexpected generation reduces or blood flow interrupts fully, stops blood supply, oxygen supply, supplies sugar etc., and this local brain tissue disintegrate is destroyed.The main cause of cerebral infarction is: 1. thromboembolism due to atherosclerosis; 2. cerebral embolism due to the embolus that heart is originated; 3. a variety of causes causes vasculitis, blood vessel injury and wound etc.Cerebral infarction is generally fallen ill in nighttime sleep, and Chang Weici WA in morning is found limb adynamia or hemiplegia, how unconscious obstacle, and blood pressure can be normal or higher, and the arteriosclerosis history can be arranged.Cerebral infarction accounts for 60%～70% of cerebral apoplexy patient sum, mainly comprises cerebral thrombosis and cerebral embolism.Because the atherosis and thrombosis in the cerebral arteries system makes, arterial lumen is narrow or inaccessible to be caused cerebral tissue local intra-arterial blood perfusion to reduce or ends caused local brain tissue necrosis for the former.
Rhizoma Chuanxiong record in the Pharmacopoeia of the People's Republic of China (version in 2010 ".Rhizoma Chuanxiong is a kind of Chinese medicine, has activating blood circulation to dissipate blood stasis, a medicinal efficacy of the analgesic therapy of regulating the flow of vital energy.Theory of Chinese medical science is paid attention to the normal operation of gas, blood, body fluid, and thinking that the stagnation of QI is not all right has a blood stasis.Cerebral ischemia is exactly due to qi stagnation blood stasis, and blood vessels are obstructed, thereby causes nervous system dysfunction.Rhizoma Chuanxiong is " gas medicine in blood ", the thin gas hero of distinguishing the flavor of, and property circulates most, and suffering is fallen apart, and to walk to alter effect very strong, and can rise and can fall apart, the rising head, side reaches extremity, and the descending sea of blood has the effect of activating blood circulation to dissipate blood stasis, circulation of qi promoting analgesic therapy, cures mainly apoplexy and enters brain headache, the diseases such as hemiplegia.Domestic Rhizoma Chuanxiong function of promoting blood circulation to disperse blood clots and mechanism have been carried out to large quantity research; confirm that Rhizoma Chuanxiong can improve brain and Peripheral Microcirculation, obviously increase cerebral blood flow, can suppress platelet activation; reduce erythrocyte and Platelet, experimental cerebral ischemia tectology and brain function are had to protective effect.
Radix Et Caulis Acanthopanacis Senticosi is recorded in the Pharmacopoeia of the People's Republic of China equally.Modern medicine studies have shown that effect characteristics and the Radix Ginseng of Radix Et Caulis Acanthopanacis Senticosi is basic identical, has the disorder of the body of adjusting, makes it to be tending towards normal function.Good antifatigue effect is arranged, remarkable than Radix Ginseng, and can significantly improve hypoxia-bearing capability.The functions such as invigorating middle warmer, benefit essence, strong will, wind-damp dispelling, strengthening bone and muscle, blood circulation and promoting silt, stomach invigorating diuresis.Take for a long time " make light of one's life by commiting suicide and endure hardships ".Radix Et Caulis Acanthopanacis Senticosi contains noticeable composition---eleutheroside, and it can stimulate the mind & body vigor.Numerous scientific publications about Radix Et Caulis Acanthopanacis Senticosi have proved its antifatigue effect, strengthen endurance and ability, increase alertness and learning capacity.Numerous usages have all obtained confirmation in human experimentation.Radix Et Caulis Acanthopanacis Senticosi is rehabilitation after being ill, bears too much pressure or anxiety, works excessive, and chronic disease causes weakly crowd and those need to reach very welcome self-medication medicine in the people on physiology and psychological performance peak.At present there is equally the report of considerable quantity to point out that it has the support immune system, recover improper hypotension, improve blood circulation, make disorderly glycolipid metabolism normalization, liver, testis, the anabolic effect of bone density and other vitals.While Chinese patent ZL94107718.7 discloses Radix Et Caulis Acanthopanacis Senticosi injection and has been used for the treatment of the cardiovascular disease such as cerebral infarction, coronary heart disease.
Radix Notoginseng is come from Compendium of Material Medica: release famous mountain paint, Radix Stephaniae Sinicae (Radix Stephaniae Dielsianae).Ancient times also claims clear ginseng, Herba Wedeliae Wallichii, Panax pseudoginseng, Typhonium flagelliforme (Lodd.) Blume, Radix Notoginseng.Radix Notoginseng has dissipating blood stasis hemostasis, the effect of subduing swelling and relieving pain.Cure mainly spitting of blood, spit blood, epistaxis, have blood in stool, metrorrhagia, and traumatic hemorrhage, breast ventral spine pain, tumbling down swells and ache.Compendium of Material Medica cloud: " Radix Notoginseng hemostasis, loose blood, analgesic therapy." " beautiful Chinese catalpa medicine solution " cloud: " Radix Notoginseng and battalion hemostasis, the clots absorbing of promoting blood circulation, clots absorbing blood and hold back fresh blood.”
But have no in prior art Rhizoma Chuanxiong, Radix Notoginseng and Radix Et Caulis Acanthopanacis Senticosi are used in conjunction with to the treatment apoplexy.
Summary of the invention
The invention provides a kind of pharmaceutical composition of new treatment apoplexy, this prescription is effectively simple, for patients with cerebral apoplexy provides a kind of new medication, selects.
The invention provides a kind of pharmaceutical composition for the treatment of apoplexy, contain the crude drug with following weight proportion in this pharmaceutical composition: Rhizoma Chuanxiong 5-40 weight portion, Radix Et Caulis Acanthopanacis Senticosi 9-40 weight portion, Radix Notoginseng 2-15 weight portion.
Further preferably contain the crude drug with following weight proportion in described pharmaceutical composition: Rhizoma Chuanxiong 13-30 weight portion, Radix Et Caulis Acanthopanacis Senticosi 27-35 weight portion, Radix Notoginseng 3-9 weight portion.
Further preferably contain the crude drug with following weight proportion in described pharmaceutical composition: Rhizoma Chuanxiong 15-20 weight portion, Radix Et Caulis Acanthopanacis Senticosi 30-35 weight portion, Radix Notoginseng 3-4 weight portion.
It is to contain the crude drug with following weight proportion that pharmaceutical composition of the present invention one of is most preferably write out a prescription: Rhizoma Chuanxiong 15 weight portions, Radix Et Caulis Acanthopanacis Senticosi 30 weight portions, Radix Notoginseng 3 weight portions.
It is to contain the crude drug with following weight proportion that pharmaceutical composition of the present invention one of is most preferably write out a prescription: Rhizoma Chuanxiong 20 weight portions, Radix Et Caulis Acanthopanacis Senticosi 30 weight portions, Radix Notoginseng 3 weight portions.
In aforementioned pharmaceutical compositions, Rhizoma Chuanxiong can be replaced one of in Ligusticum slnense, western rhizome of chuanxiong, golden rhizome of chuanxiong or eastern rhizome of chuanxiong.
In aforementioned pharmaceutical compositions, Radix Et Caulis Acanthopanacis Senticosi can be replaced by Cortex Acanthopancis.
In aforementioned pharmaceutical compositions, Radix Notoginseng can be replaced by Folium Notoginseng, flower of Radix Notoginseng or Pollen Typhae.
Apoplexy in the present invention is preferably cerebral infarction, more preferably cerebral infarction.
Pharmaceutical composition of the present invention can be made following dosage form and comprise injection, oral liquid, syrup, tablet, pill, capsule, suppository, powder, Emulsion, suspension or granule etc. together with excipient with pharmaceutically acceptable carrier.
The present invention also further provides a kind of method for preparing described pharmaceutical composition, and it adds Radix Notoginseng powder after comprising the steps: that Rhizoma Chuanxiong and Radix Et Caulis Acanthopanacis Senticosi mix decoction in filtrate, the dry pharmaceutical composition that obtains after stirring and evenly mixing.
Pharmaceutical composition of the present invention adopts line bolt method to block middle cerebral artery and causes the focal cerebral ischemia in rats damage model, observe pharmaceutical composition of the present invention and can effectively reduce rat brain tissue water content, cerebral infarction volume, and effectively improve rat neurological behavioristics etc.Experiment showed, in pharmaceutical composition of the present invention that three flavor crude drug compatibilities are used simultaneously, can obviously bring into play synergistic function, and drug effect is clear and definite, quality controllable, provide a kind of new selection for the treatment of the apoplexy medicine for clinical.And know through a large amount of clinical experimental studies, this pharmaceutical composition can embody its significant curative effect on the person.
While pharmaceutical composition of the present invention, its prescription meets theory of Chinese medical science, in side, take Rhizoma Chuanxiong as monarch drug, and the hot temperature of Rhizoma Chuanxiong is walked to alter and circulation of qi promoting, is the gas medicine in blood, has the up head, middle relieving stagnation, the effect of the descending sea of blood, the treasure in the side's of being medicine, effect is the best.Radix Et Caulis Acanthopanacis Senticosi, replenishing QI to invigorate the spleen, tonifying the kidney for tranquilization, bone and muscle strengthening.Radix Et Caulis Acanthopanacis Senticosi can promote ribonucleic acid, and synthesizing of protein, improve human body SOD and remove oxygen-derived free radicals, thereby brain cell and neurocyte are had to protective effect.The Radix Notoginseng function is enriched blood, and blood stasis removing damages, and the hemostasis nosebleed, can lead to and can mend, and has hemostasis not stay blood stasis, and new advantage is not hindered in promoting the circulation of blood; Supplementary Amplifications of the Compendium of Materia Medica say " ginseng qi-tonifying the first, Radix Notoginseng enriches blood the first, the flavor with and merit also waits, therefore the laudatory title of Panax pseudoginseng is arranged ".The blood vessel dilating of Radix Notoginseng, reduce blood pressure, improve microcirculation, increase the effect of blood flow, can effectively prevent and treat heart and brain tissues ischemia, anoxia, defying age, strengthen the learning and memory ability; Take a broad view of full side,, blood stasis dispelling and do not stay the stasis of blood, make the stasis of blood go new life for residence tonification and dredging, and QI and blood passes unimpeded, and effectively treats the persistent ailment due to cerebral infarction.
The specific embodiment
Following embodiment; only can be interpreted as it is further illustrating content of the present invention; but should not be construed the further restriction to protection domain of the present invention; all based on protection content of the present invention; ordinary skill and usual means according to those skilled in the art; under the prerequisite that does not break away from basic thought of the present invention, the modification of other various ways of making, replacement and change all should belong to protection scope of the present invention.
The preparation of embodiment mono-pharmaceutical composition C4
Rhizoma Chuanxiong 4kg and Radix Et Caulis Acanthopanacis Senticosi 6kg add 10 times of water gagings and soak 1h after mixing, heating extraction twice, each 1h, be condensed into extractum liquid after merging filtrate, Radix Notoginseng fine powder 600g to adding 100 mesh sieves in extractum liquid, in 60 ℃ of oven dryings, obtain the about 1.56kg of dry extract after stirring and evenly mixing.By the extract powder sealing, in 0～4 ℃ of refrigerator, preserve.
The preparation of embodiment bis-pharmaceutical compositions
Table 1 Chinese medicine compositions is according to the weight portion of crude drug, and according to the preparation method of embodiment mono-, wherein raw medicinal herbs equal proportion used is amplified, and prepares corresponding pharmaceutical composition.
The weight portion of the crude drug of table 1 pharmaceutical composition
| Group | Rhizoma Chuanxiong (weight portion) | Radix Et Caulis Acanthopanacis Senticosi (weight portion) | Radix Notoginseng (weight portion) |
| A | 0 | 30 | 3 |
| B | 20 | 0 | 0 |
| C1 | 40 | 9 | 15 |
| C2 | 30 | 27 | 9 |
| C3 | 18 | 35 | 4 |
| C4 | 20 | 30 | 3 |
| C5 | 15 | 30 | 3 |
| C6 | 13 | 27 | 3 |
| C7 | 10 | 15 | 6 |
| C8 | 5 | 40 | 2 |
According to following ratio and formula, use respectively the Rhizoma Chuanxiong in Ligusticum slnense, western rhizome of chuanxiong, golden rhizome of chuanxiong or eastern rhizome of chuanxiong alternative embodiment one, with Radix Et Caulis Acanthopanacis Senticosi in Cortex Acanthopancis or Folium Acanthopanacis Senticosi alternative embodiment one, with Pollen Typhae, Folium Notoginseng or a kind of Radix Notoginseng of flower of Radix Notoginseng alternative embodiment, prepare respectively corresponding pharmaceutical composition.Wherein the weight portion of concrete crude drug is composed as follows:
The C9 group: the weight proportion of medical material component is respectively Ligusticum slnense 20 weight portions, Radix Et Caulis Acanthopanacis Senticosi 30 weight portions, Radix Notoginseng 3 weight portions
The C10 group: the weight proportion of medical material component is respectively western rhizome of chuanxiong 20 weight portions, Radix Et Caulis Acanthopanacis Senticosi 30 weight portions, Radix Notoginseng 3 weight portions
The C11 group: the weight proportion of medical material component is respectively golden rhizome of chuanxiong 20 weight portions, Radix Et Caulis Acanthopanacis Senticosi 30 weight portions, Radix Notoginseng 3 weight portions
The C12 group: the weight proportion of medical material component is respectively eastern rhizome of chuanxiong 20 weight portions, Radix Et Caulis Acanthopanacis Senticosi 30 weight portions, Radix Notoginseng 3 weight portions
The C13 group: the weight proportion of medical material component is respectively Rhizoma Chuanxiong 20 weight portions, Cortex Acanthopancis 30 weight portions, Radix Notoginseng 3 weight portions
The C14 group: the weight proportion of medical material component is respectively Rhizoma Chuanxiong 20 weight portions, Radix Et Caulis Acanthopanacis Senticosi 30 weight portions, Pollen Typhae 3 weight portions
The C15 group: the weight proportion of medical material component is respectively Ligusticum slnense 20 weight portions, Cortex Acanthopancis 30 weight portions, Pollen Typhae 3 weight portions
The C16 group: the weight proportion of medical material component is respectively Rhizoma Chuanxiong 20 weight portions, Radix Et Caulis Acanthopanacis Senticosi 30 weight portions, Folium Notoginseng 3 weight portions
The C17 group: the weight proportion of medical material component is respectively Rhizoma Chuanxiong 20 weight portions, Radix Et Caulis Acanthopanacis Senticosi 30 weight portions, flower of Radix Notoginseng 3 weight portions
The C18 group: the weight proportion of medical material component is respectively Rhizoma Chuanxiong 20 weight portions, Folium Acanthopanacis Senticosi 30 weight portions, Radix Notoginseng 3 weight portions
The impact of embodiment tri-medicines on rat neuroethology, cerebral tissue water content and infarction of brain volume
1.1 test material
Experimental animal: the SD rat, complete male, the SPF level, body weight 250～320g, provided by Sichuan Academy of Medical Sciences, production licence number: the SCXK(river) 2008-24.
1.2 test reagent
Paraformaldehyde (Paraformaldehyde): the Long Huagongshijichang of Chengdu section, lot number: 20060602.
Sodium dihydrogen phosphate: the Long Huagongshijichang of Chengdu section, lot number: 20091112.
Sodium hydrogen phosphate: the Long Huagongshijichang of Chengdu section, lot number: 20080916.
Sodium hydroxide: the Long Huagongshijichang of Chengdu section, lot number: 20091103.
Red tetrazolium (Red tetrazolium, TTC): Shanghai Ling Jin Fine Chemical Co., Ltd, lot number: 20080501.
Chloral hydrate: the Long Huagongshijichang of Chengdu section, lot number: 20070101.
Nimodipine tablet: Jingxi district, Shaanxi pharmaceutcal corporation, Ltd, lot number: H61022174.
The processing of pharmaceutical composition A, B, C4: the extract powder that takes respective amount adds water after adding micro-POLYSORBATE 80 to grind and is made into suspension.
1.3 blocking middle cerebral artery, line bolt method causes the preparation of focal cerebral ischemia in rats damage model
Rats by intraperitoneal injection 10% chloral hydrate 3.0～3.3ml/kg anesthesia, dorsal position is fixed, the neck median line about 4cm of about 2mm otch that takes over, lymphoid tissue and body of gland with the mosquito forceps blunt separation under it, by ophthalmology straight forceps and curved tweezer separating muscle fascia and right carotid (CCA), in nearly crotch coiling, continue to separate external carotid artery (ECA) and internal carotid artery (ICA), in crotch ligation ECA.Along ICA toward interior about 4mm place careful separation arteria pterygopalatina, and ligation; The standby line of the nearly crotch of ICA; Cut an osculum with eye scissors, under self-control hordeolum auxiliary, fishing line (diameter 0.26mm) is inserted into to ICA, send into about 20mm and take that the sense of conflict being arranged is degree, realize the blocking-up (MCAO) to middle cerebral artery.Fasten the standby line of ICA and CCA distal end with the static line bolt.Drip appropriate gentamycin dilute solution, layer-by-layer suture otch sterilization.Keep 37 ± 0.5 ℃ of anus temperature in art, postoperative be incubated to animal clear-headed.
1.4 the impact of medicine on rat neuroethology, cerebral tissue water content and infarction of brain volume
Get healthy male rat, body weight 250～320g, be divided into sham operated rats at random, model control group, positive drug nimodipine group, tested medicine A, B, C4 group, each tested medicine group administration 650mg/Kg(650mg is the extract powder amount), the administration of positive drug group is 10mg/Kg.Each is organized administration and is every day 1 time, and gastric infusion is 21 days continuously, in modeling as stated above (sham operated rats is only separated common carotid artery) in the 14th day, in the 21st day laggard line correlation index test of last administration 1h.
1.4.1 the scoring of rat neuroethology is measured
Standards of grading with reference to " pharmacological experimental methodology " [Xu Shuyun, Bian Rulian, old repairing, pharmacological experimental methodology, Beijing: People's Health Publisher, 2001,1067] are carried out:
1. the Mus tail is observed forelimb flexing situation, as two forelimb symmetries, stretches to ground, is designated as 0 minute, as the offside forelimb of operation occurs that wrist is bent, elbow flexing, shoulder inward turning or existing wrist elbow flexing have again shoulder inward turning person, counts respectively 1,2,3,4 minute.
2. animal is placed on ground grading, pushes away respectively both shoulders and move to bilateral, check resistance, as bilateral resistance equity and strong, count 0 minute, resistance descender while promoting as the offside to operation, according to decline degree difference be divided into gently, in, weigh three degree, count respectively 1,2,3 minute.
3. the two forelimbs of animal are put on a wire netting, observed the muscular tension of two forelimbs.Muscular tension equity and the strong person of two forelimbs count 0 minute, count 1,2,3 minute according to operation offside limb tension force decline degree difference equally.
4. animal has and does not stop, to a side person of turn-taking, counting 1 minute.
According to standards of grading, full marks are 11 minutes, and mark is higher, and the delayed ischemic neurological deficits of animal is more serious, and experimental result is in Table 2.
Table 2 medicine is marked to focal cerebral ischemia in rats injured nerve behavioristics
With model control group, compare: * P<0.05, * * P<0.01
Table 2 result shows, with model control group, compares, and each administration group neuroethology score value all has reduction in various degree, and its Chinese medicine C4 group reduces comparatively obvious, and its difference has the statistical significance (P<0.01) of highly significant.
1.4.2 the mensuration of cerebral tissue water content
The rat sacrificed by decapitation, remove rhinencephalon, brain stem, cerebellum, get the brain part, be placed in weighing botle, labelling also claims weight in wet base, then puts into thermostatic drying chamber in 60 ℃ dry to constant weight (twice weight difference is less than 1%), takes out and claims its dry weight, calculate the water content of cerebral tissue by following formula, experimental result is in Table 3:
Table 3 medicine is to focal cerebral ischemia in rats injured brain tissue water content
With model control group, compare: * P<0.05, * * P<0.01
The demonstration of table 3 result, each administration group all has improvement in various degree to cerebral tissue weight in wet base, the water content of rat infarction, and its Chinese medicine C4 group is improved comparatively obvious, and its difference has the statistical significance (P<0.01) of highly significant.
1.4.3 the mensuration of infarction of brain volume
Take out rapidly brain, quick-freezing 15min left and right in-20 ℃ of refrigerators, get coronalplane and evenly be cut into the brain sheet that 2mm is thick, put into rapidly 2%TTC solution, hatch 30min in 37 ℃ of lucifuges, every 7～8min, stir once therebetween, make the brain sheet touch equably dye liquor, after dyeing, the normal brain activity sheet is rose, and infarction tissue presents white, boundary line is comparatively clearly demarcated, the brain sheet of having hatched is taken out, digital camera is taken pictures, the input computer, calculate its infarct size with computer aided video system, each brain sheet Infarction volume (equal infarct size and be multiplied by 2mm) sum is total Infarction volume.Calculate the ratio of total Infarction volume and brain cumulative volume.Experimental result is in Table 4:
Table 4 medicine damages cerebral infarction volume to focal cerebral ischemia in rats
With model control group, compare: * P<0.05, * * P<0.01
Experimental result shows, each administration group cerebral tissue Infarction volume all has minimizing in various degree, and its Chinese medicine C4 group reduces comparatively obvious, and its difference has the statistical significance (P<0.01) of highly significant.
The impact of embodiment tri-different pharmaceutical groups on rat neuroethology, cerebral tissue water content and infarction of brain volume
Experiment material, reagent and model construction are with embodiment bis-.
Get healthy male rat, body weight 250～320g, be divided into immediately sham operated rats, model control group, positive drug nimodipine group, tested medicine C1-C18 group, administering mode: each tested medicine group administration 650mg/Kg(650mg is the extract powder amount), the administration of positive drug group is 10mg/Kg, each is organized administration and is every day 1 time, gastric infusion is 21 days continuously, in modeling as stated above (sham operated rats is only separated common carotid artery) in the 14th day, modeling the 5th day, within 7 days, with method, carry out the scoring of rat neuroethology, carried out cerebral infarction volume with method in the 21st day after (being modeling the 7th day) last administration 1h, the brain water content index test, testing result is in Table 5, 6.
1, the scoring of rat neuroethology is measured
The shadow of different time points neuroethology scoring after table 5 pair focal cerebral ischemia in rats modeling
With model control group, compare: * P<0.05, * * P<0.01
Experimental result shows, with model control group, compares, and each administration group the 5th day, 7 days neural behavioristics score values after modeling all have reduction (P<0.01～0.05) in various degree.
2, to the mensuration of Rats after Focal Cerebral Ischemia cerebral infarction volume and water content
Table 6 pair Rats after Focal Cerebral Ischemia cerebral infarction volume and water content
With model control group, compare: * P<0.05, * * P<0.01
Experimental result shows, with model control group relatively, each administration group to the rat cerebral infarction volume when brain water content improvement effect (P<0.01～0.05) is in various degree all arranged.
Embodiment tetra-clinical and experimental studies
(1) inclusive criteria
1. cranium brain CT or cranium brain MRI show clear and definite infarction responsibility focus.
2. the damaged location of clear and definite nervous system sign is arranged.
3. get rid of the nervous system other diseases.
(2) exclusion standard
1. CT shows the patient of clear and definite [Dan.
2. cerebral embolism and taking the patient of other anticoagulants.
3. be in a bad way and have the feed difficulty.
4. infarction is caused by cerebrovascular malformation repeatedly.
(3) grouping: the patient who meets inclusive criteria is divided into to two groups respectively at random:
1. Rhizoma Chuanxiong 15g, Radix Et Caulis Acanthopanacis Senticosi 30g, Radix Notoginseng 3g (taking after mixing it with water)
2. Rhizoma Chuanxiong 20g, Radix Et Caulis Acanthopanacis Senticosi 30g, Radix Notoginseng 3g (taking after mixing it with water)
Rhizoma Chuanxiong and Radix Et Caulis Acanthopanacis Senticosi are mixed to immersion 40 minutes, and intense fire boils rear slow fire boiling 20 minutes, pours Radix Notoginseng powder for oral administration, potion on the one, 21 days courses for the treatment of.
(4) efficacy evaluation:
After finishing the course for the treatment of, according to the improvement situation of patient clinical symptom, divide effectively produce effects and invalid.
1. effective: main suit's doing well,improving, positive sign disappears
2. produce effects: main suit's doing well,improving, sign still exists; Or doing well,improving is not obvious, positive sign disappears
3. invalid: symptom and sign is all without improving
Result of study:
Meet inclusive criteria carry out altogether 19 examples, 7 examples that come off, other cases the results are shown in Table 7.
Table 7 clinical case result of study
Claims (10)
1. a pharmaceutical composition for the treatment of apoplexy, is characterized in that in described pharmaceutical composition containing the crude drug with weight proportion: Rhizoma Chuanxiong 5-40 weight portion, Radix Et Caulis Acanthopanacis Senticosi 9-40 weight portion, Radix Notoginseng 2-15 weight portion.
2. the pharmaceutical composition for the treatment of apoplexy according to claim 1, contain the crude drug with following weight proportion: Rhizoma Chuanxiong 13-30 weight portion, Radix Et Caulis Acanthopanacis Senticosi 27-35 weight portion, Radix Notoginseng 3-9 weight portion in pharmaceutical composition described in it is characterized in that.
3. the pharmaceutical composition for the treatment of apoplexy according to claim 2, contain the crude drug with following weight proportion: Rhizoma Chuanxiong 15-20 weight portion, Radix Et Caulis Acanthopanacis Senticosi 30-35 weight portion, Radix Notoginseng 3-4 weight portion in pharmaceutical composition described in it is characterized in that.
4. the pharmaceutical composition for the treatment of apoplexy according to claim 3, contain the crude drug with following weight proportion: Rhizoma Chuanxiong 15 weight portions, Radix Et Caulis Acanthopanacis Senticosi 30 weight portions, Radix Notoginseng 3 weight portions in pharmaceutical composition described in it is characterized in that.
5. the pharmaceutical composition for the treatment of apoplexy according to claim 3, contain the crude drug with following weight proportion: Rhizoma Chuanxiong 20 weight portions, Radix Et Caulis Acanthopanacis Senticosi 30 weight portions, Radix Notoginseng 3 weight portions in pharmaceutical composition described in it is characterized in that.
6. according to the pharmaceutical composition of the described treatment apoplexy of any one in claim 1-5, described in it is characterized in that in pharmaceutical composition Rhizoma Chuanxiong can be replaced one of in Ligusticum slnense, western rhizome of chuanxiong, golden rhizome of chuanxiong or eastern rhizome of chuanxiong; Radix Et Caulis Acanthopanacis Senticosi can be replaced by Cortex Acanthopancis; Radix Notoginseng can be replaced by Folium Notoginseng, flower of Radix Notoginseng or Pollen Typhae.
7. according to the pharmaceutical composition of the described treatment apoplexy of any one in claim 1-6, it is characterized in that described apoplexy is cerebral infarction, is preferably cerebral infarction.
8. according to the pharmaceutical composition of the described treatment apoplexy of any one in claim 1-6, the dosage form that pharmaceutical composition described in it is characterized in that is made preparation is injection, oral liquid, syrup, tablet, pill, capsule, suppository, powder, Emulsion, suspension or granule.
9. according to the pharmaceutical composition of the described treatment apoplexy of any one in claim 1-6, after the preparation method that it is characterized in that described pharmaceutical composition comprises the steps: that Rhizoma Chuanxiong and Radix Et Caulis Acanthopanacis Senticosi mix and decoct, add Radix Notoginseng powder in filtrate, the dry pharmaceutical composition that obtains after stirring and evenly mixing.
10. according to the pharmaceutical composition of the described treatment apoplexy of any one in claim 1-6, it is characterized in that described apoplexy is stroke at convalescence.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210163730.4A CN103417591B (en) | 2012-05-24 | 2012-05-24 | A kind of pharmaceutical composition for the treatment of apoplexy and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210163730.4A CN103417591B (en) | 2012-05-24 | 2012-05-24 | A kind of pharmaceutical composition for the treatment of apoplexy and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103417591A true CN103417591A (en) | 2013-12-04 |
| CN103417591B CN103417591B (en) | 2016-02-24 |
Family
ID=49643333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210163730.4A Active CN103417591B (en) | 2012-05-24 | 2012-05-24 | A kind of pharmaceutical composition for the treatment of apoplexy and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103417591B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104887791A (en) * | 2015-07-02 | 2015-09-09 | 湖南文理学院 | Chinese herbal medicine composition for resisting irritable bleeding of finless eel and use method |
| CN113577119A (en) * | 2021-07-21 | 2021-11-02 | 右江民族医学院附属医院 | Action mechanism of pseudo-ginseng on cerebral arterial thrombosis and application of action mechanism |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102357195A (en) * | 2011-11-04 | 2012-02-22 | 成都中医药大学 | Medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof |
-
2012
- 2012-05-24 CN CN201210163730.4A patent/CN103417591B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102357195A (en) * | 2011-11-04 | 2012-02-22 | 成都中医药大学 | Medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104887791A (en) * | 2015-07-02 | 2015-09-09 | 湖南文理学院 | Chinese herbal medicine composition for resisting irritable bleeding of finless eel and use method |
| CN104887791B (en) * | 2015-07-02 | 2017-12-01 | 湖南文理学院 | A kind of herbal composite and its application method of the bleeding of swamp eel resisting stress |
| CN113577119A (en) * | 2021-07-21 | 2021-11-02 | 右江民族医学院附属医院 | Action mechanism of pseudo-ginseng on cerebral arterial thrombosis and application of action mechanism |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103417591B (en) | 2016-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104474471A (en) | Traditional Chinese medicine composition for treating thyroid | |
| CN103550685B (en) | A kind of Chinese medicine composition for the treatment of lumbago and skelalgia | |
| CN104173773A (en) | Preparation with functions of treating migraine, dispelling wind and promoting blood circulation and preparation methods | |
| CN104189811A (en) | Traditional Chinese medicine composition for treating postpartum fainting and preparation method thereof | |
| CN104173517B (en) | The Chinese medicine preparation for the treatment of primary trigeminal neuralgia and preparation method | |
| CN102579610B (en) | Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof | |
| CN104623376B (en) | Be used for the treatment of prosopalgic medicine | |
| CN103417591B (en) | A kind of pharmaceutical composition for the treatment of apoplexy and preparation method thereof | |
| CN103565969A (en) | Traditional Chinese medicine composition for treating soft tissue injury and fracture | |
| CN103611100B (en) | A kind for the treatment of is had a toothache the Chinese medicine of disease | |
| CN103920058A (en) | Traditional Chinese medicine preparation for treating headache and preparation method thereof | |
| CN101804108B (en) | Traditional Chinese medicine composition for treating neurogenic headache | |
| CN106039225A (en) | Traditional Chinese medicine preparation for treating acute lumbar muscle sprain | |
| CN102145063B (en) | Traditional Chinese medicine for treating thrombocytopenic purpura | |
| CN105582154A (en) | Capsule medicine for treating wind cold induced migraine and preparation method | |
| CN105749167A (en) | Traditional Chinese medicine composition for treating amenorrhea | |
| CN103494900A (en) | Traditional Chinese medicine for treating stiff neck | |
| CN102114150A (en) | Chinese medicine oral decoction for treating endometriosis | |
| CN103705629B (en) | A kind of Chinese medicine composition for the treatment of pruritus | |
| CN107375636B (en) | Traditional Chinese medicine for treating impotence due to kidney deficiency and blood stasis and preparation method thereof | |
| CN104225342A (en) | Chinese herbal preparation for treating nephritis edema and preparation method thereof | |
| CN104083465A (en) | Medicinal liquor for treating sciatica and lumbar muscle strain and preparation method | |
| CN101700271B (en) | Traditional Chinese medicine preparation for treating apoplexy sequelae | |
| CN102406753A (en) | Chinese medicinal composition for treating Bi syndrome | |
| CN109620919A (en) | A kind of Chinese materia medica preparation and preparation method thereof for treating osteopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |